Phase II Study of a Quadruple-modality Therapy for Resectable Stage Discrete N2 III A-B Non-small Cell Lung Cancer (WJOG12119L: SQUAT trial)

Phase II Study of a Quadruple-modality Therapy: Induction Chemo-radiation Therapy Followed by Surgery with Perioperative Immunotherapy for Resectable Stage Discrete N2 III A-B Non-small Cell Lung Cancer (SQUAT trial)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224981

Enrollment

Registered

2019-12-11

Start date

2020-04-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small-cell lung cancer

Interventions

investigational material(s) Generic name etc : durvalumab INN of investigational material : durvalumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigatio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients with a histologically confirmed diagnosis of NSCLC 2.Clinical Stage T1-3N2 III A-B or T4N2 IIIB (solid diameter > 7cm) 3.Patients who were not previously treated for NSCLC 4. Patients who is possible to undergo complete resection 5. Patients to start radiation therapy based on the protocol in this study.

Exclusion criteria

Exclusion criteria: 1.Patients with active multiple primary cancer 2.Patients with autoimmune disorder including the history of treatment by immunosuppressive agent 3.Patients with interstitial lung disease on CT scan,

Design outcomes

Primary

Measure	Time frame
efficacy Major Pathologic Responses Rate (MPR; <10% residual viable tumor) (Central Pathology Review)	—

Secondary

Measure	Time frame
safety efficacy 2 years progression free survival rate 2 years disease free survival rate 2 years overall survival rate Complete resection rate (R0 rate) Treatment completion rate of protocol regimen pCR rate Difference of efficacy in patient background/PD-L1 expression. Treatment death rate Safety	—

Countries

Japan

Contacts

Public ContactKen Mizushima

West Japan Oncology Group

mizushima@wjog.jp+81-6-663-7400

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026